



Supplementary Fig. 1. Comparison of cumulative ESRD-free survival rates in 53 patients with renal manifestation at diagnosis. Patients taking MMF only showed a lower cumulative ESRD-free survival rate than those taking AZA only ($p=0.025$); however, ESRD-survival rates did not differ between patients taking MMF after AZA and those taking AZA only or between patients taking MMF only and those with MMF after AZA. ESRD, end-stage renal disease; MMF, mycophenolate mofetil; AZA, azathioprine.